PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players

NEW YORK, May 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players
http://www.reportlinker.com/p01190415/PharmaPoint-Chronic-Myeloid-Leukemia-CML---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players

Summary

GlobalData has released its pharma report, "PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing CML Market. The report identifies and analyses the key companies shaping and driving the global CML market. The report provides insight into the competitive CML landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

- Investigation of current and future market competition for CML
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of the CML sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving the CML Market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What's the next big thing in the global CML market landscape? Identify, understand and capitalize

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
3 Market Outlook 9
3.1 Global Markets 9
3.1.1 Forecast 9
3.1.2 Drivers and Barriers – Global Issues 11
4 Current and Future Players 14
4.1 Overview 14
4.2 Trends in Corporate Strategy 16
4.3 Company Profiles 17
4.3.1 Novartis 17
4.3.2 BMS 20
4.3.3 Ariad 23
4.3.4 Pfizer 26
5 Appendix 28
5.1 Bibliography 28
5.2 Abbreviations 29
5.3 Methodology 30
5.4 Forecasting Methodology 30
5.4.1 Diagnosed CML patients 30
5.4.2 Drug-treated Patients on X Line of Therapy 31
5.4.3 Drugs Included in Each Therapeutic Class 31
5.4.4 Launch and Patent Expiry Dates 31
5.4.5 General Pricing Assumptions 32
5.4.6 Compliance Assumptions for Oral TKIs 34
5.4.7 Individual Drug Assumptions 35
5.4.8 Generic Erosion 38
5.4.9 Pricing of New Market Entrants 38
5.5 Physicians and Specialists Included in this Study 39
5.6 Survey of High Prescribing Physicians 40
5.7 About the Authors 40
5.7.1 Authors 40
5.7.2 Epidemiologists 41
5.7.3 Global Director of Epidemiology and Clinical Trials Analysis 42
5.7.4 Global Head of Healthcare 43
5.8 About GlobalData 44
5.9 Contact Us 44
5.10 Disclaimer 44

List of Tables

Table 1: Global Sales Forecasts ($m) for CML, 2012–2022 10
Table 2: Chronic Myeloid Leukemia Market – Drivers and Barriers, 2013 11
Table 3: Key Companies in the CML Market, 2013 15
Table 4: Novartis' CML Portfolio Assessment, 2013 19
Table 5: Novartis SWOT Analysis, 2013 19
Table 6: BMS' CML Portfolio Assessment, 2013 21
Table 7: BMS SWOT Analysis, 2013 22
Table 8: Ariad's CML Portfolio Assessment, 2013 25
Table 9: Ariad SWOT Analysis, 2013 25
Table 10: Pfizer's CML Portfolio Assessment, 2013 27
Table 11: Pfizer SWOT Analysis, 2013 27
Table 12: Key Launch Dates 31
Table 13: Key Patent Expiries 32
Table 14: Physicians Surveyed, by Country 40

List of Figures

Figure 1: Global Sales for CML Therapeutics by Region, 2012–2022 10
Figure 2: Company Portfolio Gap Analysis in CML, 2013–2022 15

Companies Mentioned
Novartis
BMS
Ariad
Pfizer

To order this report:
Pathology Industry: PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker